Trans-Ancestral Genetic Risk Factors for Treatment-Related Type 2 Diabetes Mellitus in Survivors of Childhood Cancer
Source : https://pubmed.ncbi.nlm.nih.gov/38652878/
Our findings suggest therapy-related genetic risks contribute to the increased T2D burden among non-Hispanic Black childhood cancer survivors. Additional study of how therapy-related genetic susceptibility contributes to this disparity is...
Therapy-related genetic risks contribute to the increased burden of type 2 diabetes among non-Hispanic Black pediatric survivors of cancer.
Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee glargine) Compared With Originator Insulin Glargine (Lantus) in Patients With Type 2 Diabetes After 26 Weeks' Treatment: a Randomized Open Label Study
Source : https://pubmed.ncbi.nlm.nih.gov/38558508/
GL Glargine was similar to Lantus® in terms of immunogenicity, efficacy, and safety, based on the current study.
GL glargine was similar in terms of immunogenicity, efficacy, and safety, based on the current study.
Prediction of New-Onset Heart Failure in Patients With Type 2 Diabetes Derived From ALTITUDE and CANVAS
Source : https://pubmed.ncbi.nlm.nih.gov/38584567/
In patients with T2D, higher NT-proBNP level, TnT level and BMI are independent and externally validated predictors of new-onset HF, including patients using an SGLT2 inhibitor. This newly developed model...
In patients with type 2 diabetes, higher NT-proBNP level, troponin T level, and BMI are independent and externally validated predictors of new-onset HF, including patients taking sodium-glucose cotransporter 2 inhibitors.
Semaglutide in Patients With Obesity-Related Heart Failure and Type 2 Diabetes
Source : https://pubmed.ncbi.nlm.nih.gov/38587233/
Among patients with obesity-related heart failure with preserved ejection fraction and type 2 diabetes, semaglutide led to larger reductions in heart failure-related symptoms and physical limitations and greater weight loss...
Among patients with obesity-related HF with preserved ejection fraction and type 2 diabetes, semaglutide led to larger reductions in HF-related symptoms and physical limitations and greater weight loss than placebo at 1 year.
Experts warn that patients with obesity and type 2 diabetes do not have the luxury of waiting until 2041 for comprehensive coverage of metabolic surgery.